Glenzocimab is under clinical development by Acticor Biotech and currently in Phase III for Acute Ischemic Stroke. According to GlobalData, Phase III drugs for Acute Ischemic Stroke have a 14% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Glenzocimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Glenzocimab overview

Glenzocimab (Fab-9O12) is under development for the treatment of SARS-Cov-2-related acute respiratory distress syndrome, myocardial infarction, acute ischemic stroke and pulmonary embolism. It is a recombinant, humanized, murine monoclonal antibody fragment. It is administered through the intravenous route. The drug candidate acts on platelet glycoprotein (GP) VI and it is developed based on Catalent’s proprietary GPEX technology.

Acticor Biotech overview

Acticor Biotech operates as a clinical stage biotechnology company that develops an antithrombotic agent for the treatment of acute thrombotic diseases, including ischemic stroke and pulmonary embolism. Its pipeline product ACT017 is a humanized fragment of monoclonal antibody directed against the platelet glycoprotein VI (GPVI) which inhibits collagen-induced platelet aggregation with no effect on bleeding time nor platelet count. Acticor Biotech product finds application in the area of antithrombotic treatments suitable to treat ischemic stroke patients. The company works in partnership with research organizations including Genopole and Inserm for the development of its pipeline product. The company is a spin-off of Inserm (French National Institute of Health and Medical Research). Acticor is headquartered in Paris, France.

For a complete picture of Glenzocimab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.